Beryl Drugs Receives 'Hold' Rating from MarketsMOJO, Technical Indicators Point to Bullish Trend

Beryl Drugs, a microcap pharmaceutical company, has recently received a 'Hold' rating from MarketsMOJO. This upgrade is based on various technical indicators, such as MACD, Bollinger Band, and KST, which all point towards a bullish trend for the stock. Additionally, the company's ROCE of 14 and attractive valuation with a 1.7 Enterprise value to Capital Employed make it an attractive investment option.
Over the past year, Beryl Drugs has generated a return of 177.03%, outperforming the BSE 500 index. Its profits have also seen a significant increase of 94%, resulting in a PEG ratio of 0. This indicates that the stock is trading at a discount compared to its historical valuations.

The majority of shareholders in Beryl Drugs are non-institutional investors, which may indicate a lack of confidence from larger investors. However, the company has consistently delivered strong returns over the last 3 years, further supporting the 'Hold' rating.

On the other hand, Beryl Drugs has weak long-term fundamental strength, with an average ROCE of 5.27%. Its net sales have only grown at an annual rate of 14.92% and operating profit at 0.44% over the last 5 years. Additionally, the company has a high debt to EBITDA ratio of 3.04 times, indicating a low ability to service debt.

In the latest quarter, Beryl Drugs reported flat results with a decline in net sales of -6.47%. This may be a cause for concern for investors, but it is important to note that the company has consistently outperformed the BSE 500 index in the past 3 years.

Overall, while Beryl Drugs may have some weaknesses in its long-term fundamentals, its recent performance and technical indicators suggest a bullish trend. Investors may want to hold onto their positions for now and keep an eye on the company's future developments.